These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29635788)

  • 21. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F; Bland JM; Häggström J; Baduel L; Combes B; Lopez A; Kaltsatos V
    J Vet Intern Med; 2010; 24(2):331-41. PubMed ID: 20102506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of pimobendan in 170 cats (2006-2010).
    Macgregor JM; Rush JE; Laste NJ; Malakoff RL; Cunningham SM; Aronow N; Hall DJ; Williams J; Price LL
    J Vet Cardiol; 2011 Dec; 13(4):251-60. PubMed ID: 22030289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study.
    Besche B; Blondel T; Guillot E; Garelli-Paar C; Oyama MA
    J Vet Intern Med; 2020 Sep; 34(5):1746-1758. PubMed ID: 32767627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.
    Chetboul V; Pouchelon JL; Menard J; Blanc J; Desquilbet L; Petit A; Rougier S; Lucats L; Woehrle F;
    J Vet Intern Med; 2017 Nov; 31(6):1629-1642. PubMed ID: 28975664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M; Kooistra HS; Beijerink NJ
    J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M; Guillot E; Blondel T; Garelli-Paar C; Feng S; Heartsill S; Atkins CE
    J Vet Intern Med; 2021 Jul; 35(4):1673-1687. PubMed ID: 34028078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy.
    Borgarelli M; Haggstrom J
    Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):651-63. PubMed ID: 20610017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current use of pimobendan in canine patients with heart disease.
    Boswood A
    Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):571-80. PubMed ID: 20610012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D; Fry D
    Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of alpha blockade in the treatment of congestive heart failure associated with dirofilariasis and mitral valvular incompetence.
    Atwell RB
    Vet Rec; 1979 Feb; 104(6):114-6. PubMed ID: 452344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study).
    Summerfield NJ; Boswood A; O'Grady MR; Gordon SG; Dukes-McEwan J; Oyama MA; Smith S; Patteson M; French AT; Culshaw GJ; Braz-Ruivo L; Estrada A; O'Sullivan ML; Loureiro J; Willis R; Watson P
    J Vet Intern Med; 2012; 26(6):1337-49. PubMed ID: 23078651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
    Boswood A; Smith S; Patteson M
    Vet Rec; 2011 Feb; 168(8):222. PubMed ID: 21493561
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
    J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
    Bagardi M; Palermo V; Locatelli C; Colombo FM; Pazzagli L; Brambilla PG
    Vet Res Commun; 2022 Jun; 46(2):481-486. PubMed ID: 35034282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential prognostic indicators in dogs with advanced heart failure secondary to myxomatous mitral valve disease.
    Li CC; Chan IP; Chang CC; Hsueh T; Yang CC; Lin SL
    Vet Rec; 2024 Jul; 195(2):e4393. PubMed ID: 38959211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2022 Jun; 41():99-120. PubMed ID: 35316716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy.
    Fuentes VL; Corcoran B; French A; Schober KE; Kleemann R; Justus C
    J Vet Intern Med; 2002; 16(3):255-61. PubMed ID: 12041654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.